News ArticleMetropolis Healthcare Boosts Q2 FY27 Revenue by 16% to ₹497 Crore and PAT by 43% to ₹75 Crore
Patient volume rises 10% to 4.1 million; strong growth in specialty and Tier III city revenues; interim dividend declared at ₹1 per share
Metropolis Healthcare Limited posted strong Q2 FY27 consolidated results, with revenue increasing 16% to ₹497 crore and profit after tax rising 43% to ₹75 crore, driven by growth in patient volumes, specialty testing, and Tier III city markets. The company declared an interim dividend of ₹1 per share and continues expanding its diagnostic services network across India.
Metropolis Healthcare Limited
General / Other
Metropolis Healthcare Limited reported a 16% increase in consolidated revenue to ₹497 crore and a 43% jump in profit after tax to ₹75 crore for the quarter ended September 30, 2026, underpinned by increased patient and test volumes and growth in specialty and Tier III city markets.
The company’s patient volume grew 10% year-on-year to 4.1 million, while test volume rose 11% to 8.7 million during Q2 FY27, indicating sustained demand for organized diagnostic services.
Business-to-consumer (B2C) revenue expanded 17% to ₹289 crore, driven by lifecycle customer engagement and targeted marketing, whereas business-to-business (B2B) revenue increased 15% to ₹208 crore, supported by new clients and higher uptake of specialized tests.
TruHealth and specialty segments showed strong performance, with revenues up 20% each to ₹86 crore and ₹198 crore respectively, led by advanced genomic and cancer testing.
Revenue per patient increased 6% to ₹1,221 and revenue per test improved 5% to ₹572, achieved without any price increases, reflecting a richer test mix and better realizations.
Tier III cities remained the fastest-growing market segment, with revenue growth of approximately 20%, supported by Metropolis’s network of over 5,119 service points reaching around 750 towns across India.
Highlights
- Revenue increased 15.8% year-on-year to ₹496.8 crore in Q2 FY27.
- Profit after tax rose 42.7% year-on-year to ₹75.5 crore, with a PAT margin of 15.2%.
- EBITDA grew 23.9% to ₹134.9 crore, expanding margin by 180 basis points to 27.2%.
- Patient volume and test volume increased by 10% and 11% respectively compared to Q2 FY26.
- Metropolis declared an interim dividend of ₹1 per share for Q2 FY27.
Key Data Snapshot
What happened
- Metropolis Healthcare reported consolidated Q2 FY27 revenue of ₹497 crore, up 16% year-on-year.
- Profit after tax for the quarter increased 43% to ₹75 crore.
- The company achieved patient volume growth of 10% and test volume growth of 11%, reflecting sustained demand.
- An interim dividend of ₹1 per share was declared.
- Tier III cities showed about 20% revenue growth, highlighting expansion into smaller markets.
Key details
- B2C revenue grew 17% to ₹289 crore driven by customer engagement and marketing initiatives.
- B2B revenue increased 15% to ₹208 crore due to new clients and more specialized testing.
- TruHealth and specialty segments grew 20% each, supported by advanced genomic and cancer tests.
- Revenue per patient rose 6% without price hikes, supported by richer service mix.
- The operational footprint extended to over 5,119 service points in 750 towns.
Financial performance
- EBITDA for Q2 FY27 was ₹135 crore, up 24% year-on-year, with a margin expansion of 180 basis points to 27.2%.
- Profit before tax increased 44% to ₹102.5 crore.
- PAT margin improved by 290 basis points to 15.2%.
- H1 FY27 revenue stood at ₹947 crore, reflecting a 16% year-on-year rise.
- Sustained profitability gains were attributed to volume growth and operational efficiencies.
Background and context
- Metropolis Healthcare Limited is a leading Indian diagnostic chain established in 1981.
- The company operates over 213 laboratories and has more than 10,000 touchpoints across India and Africa.
- It offers a broad test portfolio with over 4,500 different diagnostics including advanced tests for cancer and genetic disorders.
- The company maintains a CAP proficiency score above 99.99% demonstrating quality assurance.
- Metropolis is focused on enhancing patient experience, expanding specialty services and leveraging technology in diagnostics.
Highlights
- Revenue increased 15.8% year-on-year to ₹496.8 crore in Q2 FY27.
- Profit after tax rose 42.7% year-on-year to ₹75.5 crore, with a PAT margin of 15.2%.
- EBITDA grew 23.9% to ₹134.9 crore, expanding margin by 180 basis points to 27.2%.
- Patient volume and test volume increased by 10% and 11% respectively compared to Q2 FY26.
- Metropolis declared an interim dividend of ₹1 per share for Q2 FY27.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Ms. Ameera Shah is Promoter and Executive Chairperson of Metropolis Healthcare Limited.
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
